TP53 and triple-negative breast carcinoma: Previous studies have shown that NFIB can directly promote the transcription of EZH2 (Piper et al., 2014), IGFBP5 (Perez-Casellas et al., 2009), or inhibit the transcription of p21 in TP53-mutated triple-negative breast cancer (Liu R.-Z.